ENV-101, A Novel Hedgehog Inhibitor, Increases Lung Function, and Reduces Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis: Results From a Randomized, Double-blind, Placebo-controlled Phase 2 Trial
Presented at the American Thoracic Society 2024 International Conference
T. M. Maher1, J. G. Goldin2, A. DiFrancesco3, M. de los Rios3, C. Quito3, S. Kim3, P. A. Frohna3, J. Hood3
1. PCCM, Keck School of Medicine of USC, Los Angeles, CA, United States 2. David Geffen School of Med At UCLA, Santa Monica, CA, United States 3. Endeavor BioMedicines, San Diego, CA, United States